ProPhase Labs (PRPH) said late Thursday it priced an underwritten offering of 4.17 million shares of its common stock, targeting gross proceeds of about $3 million.
Shares slumped past 45%, with intraday trading volume at over 2.1 million compared with a daily average of about 34,000.
Evolent Health (EVH) shares plunged amid heavy trading after Truist Securities cut its price target on the company's stock following Q3 results that fell short of market expectations.
Oppenheimer also adjusted Evolent's price objective to $34 from $45 while maintaining its outperform rating.
Shares of Evolent sank 43% as intraday trading volume jumped to more than 14.4 million versus a daily average of about 2.1 million.
Maravai Lifesciences (MRVI) said late Thursday it agreed to buy Officinae Bio's DNA and RNA business. Financial terms of the deal were not disclosed.
Shares of Maravai slumped 39% as intraday trading volume climbed to over 8.5 million from the stock's daily average of about 1.9 million.
Price: 0.78, Change: -0.65, Percent Change: -45.24
Comments